BioArctic (BIOA) investor relations material

Executive summary

• Leqembi (lecanemab) achieved FDA approval and U.S. launch of the subcutaneous Iqlik formulation, enhancing patient convenience and access globally, with launches in multiple countries.

• Strategic partnerships expanded, notably with Eli Lilly (including a $30M upfront payment and potential milestones up to $800M plus royalties) and Mesenkia, validating and broadening the BrainTransporter platform into CNS and oncology applications.

• The company maintains a strong financial position, with SEK 2 billion in cash at Q2 end, rising to over SEK 2.3 billion after the Lilly payment in July.

• Pipeline progress includes positive safety data for exidavnemab in phase II-A, ongoing IND-enabling activities for BAN2238, and clinical milestones expected in 2027.

• Recurring revenues are robust, and profitability is expected for the full year 2026.

Financial highlights

• Q2 net revenues were SEK 248 million, with recurring revenues nearing SEK 200 million per quarter and SEK 51 million recognized from Novartis.

• Leqembi global Q2 sales reached JPY 29.3 billion ($184 million), up 12% sequentially and 27% year-over-year.

• Royalties from Leqembi grew 12% to SEK 179.4 million; adjusted for prior year stockpiling, annual growth would be 43%.

• Operating costs increased to SEK 232 million in Q2, reflecting higher R&D investment, with R&D comprising up to 75% of costs.

• Cash and cash equivalents stood at SEK 2 billion at Q2 end, with a dividend of SEK 177 million paid in June.

Outlook and guidance

• Full-year 2026 operating costs expected to rise 40%-60% year-over-year, with profitability still anticipated.

• Eisai maintains FY2026 Leqembi sales forecast at JPY 143.5 billion (~$910 million), with SEK 880 million in royalties projected.

• Subcutaneous Leqembi launches in Japan and China expected in late 2026 and early 2027, respectively.

• Exidavnemab phase II-A results expected by year-end, with phase II-B initiation planned for 2027.